Clinical Trials Arena on MSN9d
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...
Neurocrine’s ingrezza shows efficacy in tardive dyskinesia study
Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...
Nasdaq9d
Neurocrine's INGREZZA Shows High Remission Rates In Tardive Dyskinesia Study
(RTTNews) - Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in ...
The Pharma Letter9d
Neurocrine touts further positive trial results for Ingrezza
US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...
The Victoria Advocate10d
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side ...
Yahoo Finance9d
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).